News
Boehringer & IBM announce blockchain partnership for clinical trials
February 18 by Pharma IQ NewsThe companies plan to explore the use of blockchain in clinical trials in Canada to improve data integrity and transparency
4 Steps the FDA plan to take to improve the use of AI and RWE in clinical trials
February 05 by Natasha TaylorGottlieb pushes for the use of new approaches and new technology to make more reliable treatment decisions
FDA braces for increase in cell and gene therapies
January 22 by Natasha TaylorBy 2020, the FDA expects to receive over 200 IND applications per year, with approvals reaching 20 per year in 2025
Doubts over ‘No Deal’ rise: How Pharma is preparing for Brexit
January 22 by Pharmaceuticals & Biotechnology EditorFollowing the majority rejection of a proposed withdrawal agreement, the pharmaceutical industry is left to prepare for a 'no deal' scenario
Deloitte predicts R&D productivity slump: Is AI the answer to profitable drug discovery?
January 15 by Natasha TaylorWith the cost of development doubling in recent years and projected sales falling, it is time to explore new models and invest in technology
Bristol-Myers to acquire Celgene for $74 billion: Is it time for the M&A biotech boom?
January 08 by Pharma IQBristol-Myers acquisition of Celgene would create a powerful pharma company with leading positions in immune-oncology and the treatment of blood cancers.
CRO market growing steadily but global shifts expected
December 11 by Natasha TaylorLatest report predicts that blockbuster M&As will raise capabilities, but might not be enough to stop companies looking to emerging markets.
Repositive connects oncologists with cancer models
October 10 by Pharma IQ NewsRepositive launches limited-time free Personal Shopper Service, to connect researchers with difficult-to-source translational cancer models
Brexit and the search for talent
October 09 by Pharmaceuticals & Biotechnology EditorLeading CRO Richmond Pharmacology has released a briefing covering the issues of overseas staffing in the wake of the Brexit decision.
Digital transformation in pharma: a discussion with Pfizer [PODCAST]
October 04 by Seth AdlerThe AI Network Podcast interviewed Anil Bhavani of Pfizer on transformation and change management.
Compound management market to almost double by 2023
September 24 by Pharmaceuticals & Biotechnology EditorThe global compound control market is projected to reach $424.5 million in 2023 from $215.3m in 2018, at CAGR of 14.5 per cent.
Disclosure, finances, and the oncologist
September 11 by Pharmaceuticals & Biotechnology EditorDr José Baselga, CMO at the Memorial Sloan Kettering Cancer Centre, has neglected to fully disclose his vested interest in drug company sponsors.